cholesterol content, 6 which may theoretically reduce the risk of developing gallstones, a risk factor for pancreatitis.
Hypertriglyceridemia has been reported to be the third most common cause of pancreatitis. 7 This has led to major guidelines for lipid-modifying therapies, including advice to commence triglyceride-lowering therapy, usually fibrates, in persons with moderate and severe hypertriglyceridemia (above 400 to 500 mg/dL [to convert to mmol/L, multiply by 0.0113]). 8, 9 However, highquality evidence for this approach is lacking, and only observational data exist. 10, 11 Indeed, there is concern that fibrates might increase the risk of pancreatitis in individuals with triglyceride levels lower than those mentioned in guidelines. 12 Fibrates increase the cholesterol concentration in bile and may increase the risk of gallstones. 13, 14 However, few large randomized placebocontrolled trials of fibrate therapy have published data on pancreatitis.
Consequently,theassociationsbetween both types of lipid-modifying therapy and the risk of pancreatitis are uncertain. We therefore examined the associations between use of a statin or a fibrate and the incidence of pancreatitis by conducting collaborative meta-analyses of published and unpublished data from the relevant large randomized clinical trials.
METHODS
We gathered data from large randomized end-point trials primarily designed to assess the effects of statin therapy (including both placebo-and standard care-controlledtrialsplusintensive-dose/ moderate-dose trials) or fibrate therapy on cardiovascular events. Inclusion criteria were trials with 1000 or more participants exposed to randomized therapy withaminimummeanfollow-upof1year, as in previous large meta-analyses of statin trials. 15 We excluded trials conducted inpatientswithpreviousorgantransplantation or those receiving hemodialysis as well as trials comparing combination therapy with placebo.
WesearchedMEDLINE,EMBASE,and Web of Science databases using the terms statin, HMG CoA reductase inhibitor, and fibrate and also names of individual statins (atorvastatin, fluvastatin, lovastatin, pitavastatin,pravastatin,rosuvastatin,simvastatin) and fibrates (bezafibrate, ciprofibrate, clofibrate, fenofibrate, gemfibrozil) as title words and keywords, limited to studies defined as randomized controlled trials, to identify relevant studies performed in adult patients (initial search on October 28, 2011; search updated June 9, 2012) and published from January 1, 1972 (fibrate trials), or January 1, 1994 (statin trials), until June 9, 2012 (FIGURE 1), without language restrictions. Reference lists for the studies identified in the literature search were searched for additional studies. The US Food and Drug Administration website was also searched for trial reports containing relevant data. Abstracts, manuscripts, and reports were reviewed independently by 2 readers (D.P., P.W.) in an unblinded fashion. A third reviewer (N.S.) settled discrepancies. In the small number of trials in which published data regarding incident pancreatitis and change in triglyceride levels were available, these data were tabulated. In the majority of trials in which no relevant data were available, trial investigators were contacted with a request to provide the required information. Afterthefullarticleswerereviewedand data were received from collaborators, 21 statin trials 5, (TABLE 1) and 7 fibrate  trials  12,37-43 (TABLE 2) were included in the analyses. Because unpublished data were madeavailableforboththeHelsinkiHeart Study 40 and its smaller ancillary study 44 conductedinsimilargroupsofparticipants randomizedtothesametherapiesoverthe same follow-up times, these results were combined as a single overall study.
Data Sources
Published data for incident pancreatitis were available from 2 statin trials 5,22,36 and 4 fibrate trials. 12, [37] [38] [39] 41 Unpublished data were collected from 19 statin trials [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] and 3 fibrate trials. 40, 42, 43 To examine whether there was a relationship between theextentoftriglycerideloweringbetween active and control therapy groups in the trials and risk of pancreatitis, we collected data on average change in triglyceride levels at 1 year. A PRISMA checklist was provided to the journal at the time of manuscript submission. 45 
Quality Assessment
Two authors (D.P., P.W.) used an established tool, the Jadad score, to independently evaluate the quality of each trial. 46 The Jadad score is designed to assess trials with regard to method of randomization, whether the trial is double-blinded, and whether withdrawals/dropouts are described, resulting in a score of up to 5 points. A third reviewer (N.S.) was available to resolve any disagreement by consensus and discussion.
End Points
A patient was considered to have developed pancreatitis during the trial if this Diseases classifications (10th revision: K85, K86.0, K86.1; ninth revision: 577.0, 577.1), according to the preference of each trial's investigators. All reports of pancreatitis were included, regardless of suggested etiology (information regarding alcohol intake was not available) or whether the condition was described as acute, chronic, or neither, based on the rationale that such additional data may have been largely absent or variably reported across trials.
Statistical Analysis
To identify potential associations of lipidmodifying therapies with the risk of developing pancreatitis, we calculated risk ratios (RRs) as the ratio of cumulative incidence and 95% CIs from the available data for all trial participants at baseline and for those who developed pancreatitis during trial follow-up. Study-specific RRs were pooled using a random-effects model meta-analysis as the preferable approachtomanagepotentialbetween-study heterogeneity that may have been introduced by the differing methods for identifying participants with incident pancreatitis available in the trials and different trial populations. For trials with no events with randomized or control therapy, a nominal amount (0.5 cases) was added to the results for both trial groups.
Statistical heterogeneity across studies was quantified using both the 2 (or Cochran Q statistic) and I 2 statistics, with PϾ.10 considered statistically nonsignificant. The I 2 statistic is derived from the Q statistic ([Q−df/Q]ϫ100) and provides a measure of the proportion of the overall variation attributable to betweenstudy heterogeneity. 47 Placebo-and standard care-controlled statin trials plus intensive-dose/ moderate-dose statin trials were analyzed both separately (with comparison of analyses by fixed-effect inversevariance method) and in a combined analysis. In sensitivity analyses, only trials with previously published pancreatitis data were examined; fixed-effects model meta-analyses were also performed. We assessed the potential for publication bias through formal statistical testing, namely, funnel plots and Egger tests. To evaluate the potential relationship between the associations of lipid-modifying agents with incident pancreatitis and relative reductions in triglyceride levels achieved at 1 year using statins and fibrates, respectively, random-effects meta-regression analyses were performed.
All P values were 2-sided, and PϽ.05 was considered statistically significant for the meta-analyses and meta-regression analyses. Analyses were conducted using Stata version 10.1 (StataCorp).
RESULTS

Statin Therapy and Pancreatitis
Twenty-one randomized clinical trials of statin therapy, 2 with published data regarding incident pancreatitis and 19 with unpublished data, provided data on 153 414participantsoveraweightedmean follow-up period of 4.3 (SD, 1.6) years. Baseline average triglyceride levels in the trials varied from 118 mg/dL to 187 mg/ dL. Trials were of high quality, with a median Jadad score of 5 (range, 3-5) and 100% agreement between reviewers.
In 16 placebo-and standard carecontrolled statin trials with 113 800 participants conducted over 4.1 (SD, 1. FIGURE 2 ). This represents a number needed to treat Figure 2 ). There was againlimitedheterogeneitybetweenthese trials for incident pancreatitis ( 2 =1.29; I 2 =0%).
There was no evidence of statistical heterogeneity between the analyses of placebo-controlled trials and intensivedose/moderate-dose trials (P = .79 for interaction).
In the combined data set of 21 FIGURE 3 ). This represents a number needed to harm For abbreviations, see Table 1 . Size of data markers indicates relative weight of the study (from random-effects analysis).
of 935 (95% CI, 388 to Ͼ50 000) over 5 years. There was limited heterogeneity between trials for incident pancreatitis ( 2 =4.48; I 2 =0%). Likewise, there was no evidence of publication bias (P=.59) (eFigure 1B). Meta-regression analysis found no relationship across the trials between risk of pancreatitis and reduction in triglyceride levels at 1 year across the trials (P = .81) (eFigure 2B), although this analysis was of limited value given the limited statistical heterogeneity between trial-specific RRs and the similar relative reductions in triglyceride levels achieved across the trials.
Using a fixed-effects model approach produced results identical to those achieved using the random-effects model ( 
COMMENT
This report of pooled randomized trial data demonstrates that use of statin therapy was associated with a reduction in the number of patients developing pancreatitis. Broadly similar results were obtained for statin compared with placebo as well as for intensivedose statin therapy compared with moderate-dose therapy, in keeping with a dose-dependent association. However, we did not demonstrate an association between use of fibrate therapy and risk of pancreatitis.
Previously published case reports and observational pharmacoepidemiologic studies have demonstrated an association between statin therapy and increased risk of pancreatitis. [1] [2] [3] [4] However, such analyses are susceptible to bias by unmeasured confounders and to confounding by indication. The present analysis, however, indicates that statin therapy may be associated with a reduced risk of pancreatitis overall. Although we cannot completely exclude the possibility that statin therapy may lead to very occasional idiosyncratic cases of pancreatitis, the randomized trial data appear reassuring. Unlike fibrates, statins are not known to increase the risk of developing gallstones. 48 Studies showing both a reduction in bile cholesterol levels and an association with reduced risk of gallstones with statin therapy suggest the possibility of a protective effect. 6, 49 Furthermore, studies conducted in animal models suggest that statin therapy may be beneficial in both established acute pancreatitis and chronic pancreatitis. [50] [51] [52] Major guidelines of lipid-modifying therapy such as the National Cholesterol Education Program Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) 8 and the NationalInstituteforHealthandClinicalExcellence (NICE) Type 2 Diabetes guideline 9 suggesttheadditionoffibratetherapy in patients with moderately elevated triglyceride levels and above (Ͼ400 mg/dL and Ͼ500 mg/dL, respectively). This is based on the rationale that hypertriglyceridemiaisawell-recognizedcauseofpancreatitis and that lowering of triglyceride levels should be clinically beneficial. 7 However, no convincing trial data exist to support use of any agents for preventionofpancreatitisinthisclinicalsituation. Participants in the Coronary Drug Project assigned to clofibrate were at 50% higher risk of developing cholelithiasis or cholecystitis than those receiving placebo, 13 andgallstonesareawell-recognizedcause of pancreatitis. In addition, it has been demonstratedinsmallclinicalstudiesthat both fenofibrate-a fibrate thought less likelytocausegallstones-andbezafibrate increase the cholesterol content of bile, thereby theoretically increasing the risk ofdevelopinggallstones.
14,53 Followingthe CoronaryDrugProject,otherlargefibrate trials did not find a significant increase in the incidence of gallbladder disease, although the total number of cases was small. 40, 41, 43 Our analysis did not demonstrate an association between fibrate therapy and risk of pancreatitis, although the analysis may have lacked statistical powertoshowanincreasedriskinpatients with slightly elevated triglyceride levels (the range at baseline in the trials we examined was 145-184 mg/dL). It remains possible,however,thatfibratesmighthave adifferentneteffectinpatientswithhigher triglyceride levels.
Although the present results for both statins and fibrates should be considered hypothesis-generating and the number of pancreatitis cases was small in this trial population at low risk of pancreatitis, the analysis raises questions regarding the choice of lipid-modifying agents in pa- For abbreviations, see Table 2 . Size of data markers indicates relative weight of the study (from random-effects analysis).
tients with hypertriglyceridemia. In those with slightly elevated triglyceride levels, statins appear better supported by the available data than fibrates for preventing pancreatitis. Lifestyle modifications also remain important to improve lipid profiles in such individuals. In patients with severe hypertriglyceridemia, a trial comparing fibrates and statins for preventing pancreatitis would be clinically valuable.
Strengths of this meta-analysis are that the analysis was conducted using data from randomized trials, which avoids most of the potential bias of unmeasured confounders encountered in observational studies, and that we were able to include data from almost all of the relevant trials, both published and unpublished, thereby maximizing power and providing the best answer possible with existing data.
Thismeta-analysisalsohasseverallimitations. First, pancreatitis was not a prespecified end point in the trials, which were primarily designed to assess the effect of lipid-modifying therapy on cardiovascular events. However, limited statistical heterogeneity between trial results for statins and fibrates, plus evidence of a dose-dependent association for statins, provides confidence in the findings. Second, the occurrence of pancreatitis was not recorded in a standardized way, with resultant variation between trials. Therefore these results, especially for fibrate therapy when there were relatively few events dominated by 2 trials, 12, 43 should be interpreted with caution.
Third, because it was felt unlikely that the cause of pancreatitis would have been consistently recorded in an accurate way across trials, we were unable to examine specific causes such as gallstones. Likewise, we were unable to separate reports of pancreatitis into acute and chronic cases. However, given that the majority of trials used the presence of hepatobiliary disease as an exclusion criterion, it is highly likely that the majority of cases included in this report represent de novo acute pancreatitis. This is supported by evidence from SHARP. 5 Fourth, we did not have access to individual-participant data, which may have reduced our ability to identify any relationship with the extent of triglyceride lowering. Fifth, because the trials tended to exclude participants with marked hypertriglyceridemia, these findings may not necessarily be generalizabletothatspecificgroupofpatients.
In summary, pooled analyses of randomized trial data suggest that statin therapy is associated with a reduction in theriskofpancreatitisinpatientswithnormal or mildly elevated triglyceride levels. 
